IL-33 potentiates histaminergic itch

• Published in: Journal of allergy and clinical immunology Vol. 153; no. 3; pp. 852 - 859.e3
• Main Authors: Trier, Anna M., Ver Heul, Aaron M., Fredman, Avery, Le, Victoria, Wang, Zhen, Auyeung, Kelsey, Meixiong, James, Lovato, Paola, Holtzman, Michael J., Wang, Fang, Dong, Xinzhong, Ji, Andrew L., Kim, Brian S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2024
• Subjects: Animals; Chronic spontaneous urticaria; histamine; Histamine - metabolism; Histamine Antagonists; Humans; IL-13; IL-33; Interleukin-13 - genetics; Interleukin-13 - metabolism; Interleukin-33 - metabolism; itch; mast cell; Mice; Mice, Knockout; neuroimmunology; Pruritus - pathology; Quality of Life; Skin - pathology; itch; LM; histamine; ImmGen; CSU; mast cell; OSM; Chronic spontaneous urticaria; IL-13; C48/80; IL-33; neuroimmunology; His; scRNA-Seq; OVA; IL-33R; WT
• ISSN: 0091-6749; 1097-6825; 1097-6825
• DOI: 10.1016/j.jaci.2023.08.038

[Display omitted] Itch is a common symptom that can greatly diminish quality of life. Histamine is a potent endogenous pruritogen, and while antihistamines are often the first-line treatment for itch, in conditions like chronic spontaneous urticaria (CSU), many patients remain symptomatic while receiving maximal doses. Mechanisms that drive resistance to antihistamines are poorly defined. Signaling of the alarmin cytokine IL-33 in sensory neurons is postulated to drive chronic itch by inducing neuronal sensitization to pruritogens. Thus, we sought to determine if IL-33 can augment histamine-induced (histaminergic) itch. Itch behavior was assessed in response to histamine after IL-33 or saline administration. Various stimuli and conditional and global knockout mice were utilized to dissect cellular mechanisms. Multiple existing transcriptomic data sets were evaluated, including single-cell RNA sequencing of human and mouse skin, microarrays of isolated mouse mast cells at steady state and after stimulation with IL-33, and microarrays of skin biopsy samples from subjects with CSU and healthy controls. IL-33 amplifies histaminergic itch independent of IL-33 signaling in sensory neurons. Mast cells are the top expressors of the IL-33 receptor in both human and mouse skin. When stimulated by IL-33, mouse mast cells significantly increase IL-13 levels. Enhancement of histaminergic itch by IL-33 relies on a mast cell– and IL-13–dependent mechanism. IL-33 receptor expression is increased in lesional skin of subjects with CSU compared to healthy controls. Our findings suggest that IL-33 signaling may be a key driver of histaminergic itch in mast cell–associated pruritic conditions such as CSU.